Abstract
The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled angiographic trial that tested the efficacy of colestipol plus niacin therapy for the reduction of blood low-density lipoprotein cholesterol level and the increase of blood high-density lipoprotein cholesterol level. One hundred sixty-two nonsmoking men from 40 to 59 years old who had udergone coronary bypass surgery were followed for 2 years and of these, 103 (57 drug treated, 46 placebo treated) were followed for 4 years. Average 4-year drug dose levels were niacin, 4.2 g/d, and colestipol, 30 g/d. Frozen plasma samples drawn during the fourth trial year and after cessation of therapy were assayed for homocyst(e)ine There was a statistically significant difference between the drug and placebo groups with respect to on-trial homocyst(e)ine, (P < 0.01), with the drug group demonstrating higher levels. After therapy was withdrawn, there was a significant group difference in homocyst(e)ine change, (P < 0.001), with a median decrease of 5.99 nmol/mL in the drug group and a median increase of 0.98 nmol/mL in the placebo group. These results indicate that homocyst(e)ine levels are elevated by treatment with colestipol plus niacin.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
